Deprenyl decreases an endogenous parkinsonism-inducing compound, 1-benzyl-1,2,3,4-tetrahydroisoquinoline in mice: in vivo and in vitro studies

Brain Res. 1998 Mar 23;787(2):341-3. doi: 10.1016/s0006-8993(97)01560-6.

Abstract

We examined the effect of deprenyl, a promising drug for the therapy of Parkinson's disease on the formation of a parkinsonism-inducing compound, 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1BnTIQ). The 1BnTIQ content was significantly decreased in the brain of deprenyl-treated mouse in vivo, and deprenyl also inhibited 1BnTIQ formation from phenethylamine by a mouse brain homogenate supernatant in vitro. In vivo, the content of a parkinsonism-preventing compound, 1-methyl-1,2,3, 4-tetrahydroisoquinoline (1MeTIQ) was slightly increased in mice injected with deprenyl. The marked decrease of the ratio of 1BnTIQ to 1MeTIQ might play a role in the clinical effect of deprenyl.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Arrhythmia Agents / metabolism*
  • Brain Chemistry / drug effects*
  • Chromatography, Gas
  • Depression, Chemical
  • In Vitro Techniques
  • Isoquinolines / metabolism*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Monoamine Oxidase Inhibitors / pharmacology*
  • Parkinson Disease, Secondary / metabolism*
  • Phenethylamines / metabolism
  • Selegiline / pharmacology*
  • Tetrahydroisoquinolines*

Substances

  • Anti-Arrhythmia Agents
  • Isoquinolines
  • Monoamine Oxidase Inhibitors
  • Phenethylamines
  • Tetrahydroisoquinolines
  • Selegiline
  • 1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline